That Macquarie article looks sus.Goldman Sach's latest report is accurate (no mixup with another company) and no change to the buy recommendation with a 12-month target of 65c.
MSB Mesoblast resubmits US FDA application for approval of Ryoncil in children with graft vs host disease; shares dip -4%